Evans Jay T, Cluff Christopher W, Johnson David A, Lacy Michael J, Persing David H, Baldridge Jory R
Corixa Corporation, Hamilton, MT 59840, USA.
Expert Rev Vaccines. 2003 Apr;2(2):219-29. doi: 10.1586/14760584.2.2.219.
MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of lipopolysaccharide. MPL adjuvant has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. With over 33,000 doses administered to date, MPL adjuvant has emerged as a safe and effective vaccine adjuvant. Recently, scientists at Corixa Corporation have developed a library of synthetic lipid A mimetics (aminoalkyl glucosaminide 4-phosphates) with demonstrated immunostimulatory properties. Similar to MPL adjuvant, these synthetic compounds signal through Toll-like receptor 4 to stimulate the innate immune system. One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies.
MPL（Corixa）佐剂是一种化学修饰的脂多糖衍生物，其毒性大大降低，同时保留了脂多糖的大部分免疫刺激活性。MPL佐剂作为预防性和治疗性疫苗的成分，已广泛用于针对传染病、癌症和过敏症的临床试验。迄今为止，已施用超过33000剂，MPL佐剂已成为一种安全有效的疫苗佐剂。最近，Corixa公司的科学家开发了一系列具有免疫刺激特性的合成类脂A模拟物（氨基烷基葡糖胺4-磷酸）。与MPL佐剂类似，这些合成化合物通过Toll样受体4发出信号，刺激先天免疫系统。其中一种化合物Ribi.529（RC-529）已成为一种领先的佐剂，在临床前和临床研究中，其疗效和安全性与MPL佐剂相似。
